Finding new drugs to target SATB2 in pancreatic cancer
Official title: Discovery of SATB2 Inhibitors for Pancreatic Cancer
Funded at Glax, LLC · NIH-11026366 · Data updated 2026-11-12
This study is looking at new safe medications that can block a protein called SATB2, which is found in high amounts in pancreatic cancer cells, to see if this can help slow down tumor growth and make treatments more effective for patients.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Glax, LLC NIH-funded |
| Lab location | 1 site (Wilmington, United States) |
| Project start | February 5, 2024 |
| Project end | January 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $55,000 |
| NIH project number | 5R03CA286643-02 |
| Project ID | NIH-11026366 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with pancreatic cancer, particularly those who have not responded well to existing therapies.
✕Less likely to help
Patients with early-stage pancreatic cancer who are responding well to current treatments may not benefit from this research.
What this research studies
This research focuses on developing new non-toxic drugs that inhibit SATB2, a protein that is highly expressed in pancreatic cancer cells and cancer stem cells. The study aims to understand how SATB2 contributes to the growth and survival of these cancer cells, which are often resistant to current treatments. By targeting SATB2, the researchers hope to reduce tumor growth and improve patient outcomes. The approach involves investigating the role of SATB2 in gene expression and cancer cell behavior.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatments for pancreatic cancer patients.
How similar studies have gone: While targeting SATB2 is a novel approach, similar strategies targeting cancer stem cells have shown promise in other types of cancer.
Where this research is happening
-
Glax, LLC
Wilmington, United States Active
Researchers
- Principal investigator: Srivastava, Rakesh K. — Glax, LLC
- Study coordinator: Srivastava, Rakesh K.
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.